Bottom-up Structural Design of Crystalline Drug-Excipient Composite Microparticles via Microfluidic Droplet-based Processing

Eunice W. Q. Yeap,‡ Denise Z. L. Ng,‡ Ammu Prhashanna,‡ Ambika Somasundar,‡ Andrew J. Acevedo,§ Qisong Xu,‡ Fatma Salahioglu,¶ Marc V. Garland,† and Saif A. Khan*‡

†Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore 117576, Singapore
§Department of Biomedical Engineering, Boston University, 44 Cumming Street, Boston, Massachusetts 02215, United States
¶Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research), 1 Pesek Road, Jurong Island, Singapore, 627833, Singapore

Supporting Information

ABSTRACT: We present a simple, bottom up method for the structural design of solid microparticles containing crystalline drug and excipient using microfluidic droplet-based processing. In a model system comprising 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY) as the drug and ethyl cellulose (EC) as the excipient, we demonstrate a diversity of particle structures, with exquisite control over the structural outcome at the single-particle level. Within microfluidic droplets containing drug and excipient, tuning droplet composition and solvent removal rates allows us to controllably access structural diversity via an interplay of three physical processes (liquid–liquid phase separation, drug crystallization, and polymer vitrification) occurring during solvent removal. Specifically, we demonstrate two levels of structural control—a coarse “macro” particle structure and a finer “micro” structure. Further, we elucidate the key mechanistic elements responsible for the observed structural diversity using a combination of systematic experiments, thermodynamic arguments based on a three-component phase diagram, and dissipative particle dynamics simulations. We validate our method with two different excipient and drug combinations—ROY and poly(lactic-co-glycolic acid), and EC and carbamazepine (CBZ). Finally, we present preliminary investigations of in vitro drug release from two different types of CBZ–EC particles, highlighting how structural control allows the design of drug release profiles.

1. INTRODUCTION

The design, formulation, and manufacturing of engineered composites containing a solid active pharmaceutical ingredient (API) and polymeric excipient(s), with precisely tailored composition and structure, have been of tremendous academic and industrial interest in recent years for two primary reasons. First, from the perspective of pharmaceutical materials science and product design, engineered solid composites allow new and exciting possibilities in the creation of drug products with tailored dosage and release profiles.1−5 Second, and equally importantly, such granular materials can have enhanced processability in terms of flow properties6 and enable paradigm-shifting intensification (and simplification) of the traditional pharmaceutical manufacturing workflow, while also facilitating agile and decentralized supply chain models that can rapidly respond to evolving market forces.7,8 In particular, the latter is made possible by the use of engineered composites as intermediate drug products, which can be converted to the final dose form on-demand with minimal further processing, in a customized and decentralized fashion. Recent demonstrations of solid drug-polymer composites include amorphous solid dispersions,9 microparticles10,11 and hydrogels laden with the API in the crystalline form.1

This paper focuses on a recently developed technique that combines microfluidic generation of droplets carrying dissolved API (with or without dissolved excipient material), and evaporative crystallization/solidification in thin films, to produce monodisperse spherical microparticles of crystalline API coformulated with solid excipient in a “bottom up” fashion.12,13 The formulation of both hydrophilic and hydrophobic drug molecules has been demonstrated using this technique. Interestingly, it has also been shown that the simultaneous solidification of hydrophobic drugs, such as 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY) or carbamazepine (CBZ), with a polymeric excipient, such as ethyl cellulose (EC), not only enables shorter crystallization times, but also allows a remarkable degree of process-based selectivity over the polymorphic form of the

Received: November 22, 2016
Revised: March 31, 2017
Published: April 21, 2017

DOI: 10.1021/acs.cgd.6b01701
crystalline drug. This method has the potential to be widely adopted as a simple method for single-step crystallization and direct compaction of drugs and excipients, which circumvents several energy intensive downstream steps in the pharmaceutical manufacturing workflow, while also allowing the creation of "designer" drug products with a hitherto unprecedented level of control over solid particle attributes.

These demonstrations notwithstanding, the complexity of the (at least) three-component drug–excipient–solvent system confined within microscale droplets, and the attendant complexity of the dynamic processes of phase separation and drug/excipient solidification that occur within the droplets, make it challenging to develop general guidelines that allow a priori design of the structure and composition of these drug–excipient composites. Therefore, in this paper, we focus on a phenomenological study of the dynamics of simultaneous API/excipient solidification and structure formation within evaporating microfluidic emulsion droplets, in an attempt to delineate the basic and general elements of these processes.

In a model system comprising 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY) as the drug and ethyl cellulose (EC) as the excipient, we are able to demonstrate a diversity of particle structures, with exquisite control over the structural outcome at the single-particle level. Starting with microfluidic droplets containing drug and excipient dissolved in a common solvent, tuning droplet composition and solvent removal rates allows us to controllably access structural diversity via an interplay of the three physical processes (liquid–liquid phase separation, drug crystallization, and polymer vitrification) occurring within each droplet during solvent removal. Specifically, we demonstrate two levels of structural control—a coarse "macro" particle structure and a finer "micro" structure with our chosen model system. Further, we elucidate the key mechanistic elements responsible for the observed structural diversity using a combination of systematic experiments, thermodynamic arguments based on a three-component phase diagram, and dissipative particle dynamics (DPD) simulations. We validate our method by applying it to fabricate microparticles containing ROY and a different matrix material, poly(lactic-co-glycolic acid) (PLGA), and those comprising EC and a different drug, carbamazepine (CBZ). Finally, we present preliminary investigations of in vitro drug release from two different types of CBZ–EC particles, highlighting how structural control allows the design of drug release profiles.

2. EXPERIMENTAL SECTION

2.1. Materials. Poly(vinyl) alcohol (PVA) (M.W. 67,000), dichloromethane (DCM) (99.5%), ethyl cellulose (EC) (viscosity 10 cP), poly(lactic-co-glycolic acid) (PLGA) (50:50), and carbamazepine (CBZ) were purchased from Sigma-Aldrich (Singapore) and used as received. 5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY) was purchased from Nanjing Chemlin Chemical Industry Co. Ltd., China. Ultrapure water (18.3 MQ) obtained using a Millipore Milli-Q purification system was used to prepare aqueous PVA solution. Harvard PHD 22/2000 series syringe pumps were used to dispense fluids into the emulsion generator. Square and cylindrical glass capillaries of I.D. 1 mm and 0.7 mm respectively were purchased from Arte Glass Associates Co. Ltd., Japan.

2.2. Methods. (i) Fabrication of drug-excipient microparticles: A glass capillary microfluidic setup for emulsion generation was assembled with square and cylindrical glass capillaries, as reported previously. First, the cylindrical glass capillary surfaces were rendered hydrophilic through treatment with oxygen plasma (100 W) for 120 s. Thereafter, the square and cylindrical glass capillary were assembled coaxially. The aqueous continuous phase (W) used was 1.5 wt % PVA in ultrapure water. The compositions of the dispersed phase (O) used in the synthesis of ROY–EC microparticles were set at ROY and EC concentrations of 120, 320, 420 mg/mL and 20, 40, 80 mg/mL of DCM respectively. For validation experiments, the dispersed phase for the synthesis of CBZ–EC microparticles, CBZ and EC concentrations were both set at a fixed mass ratio of 1 at either 40 or 60 mg/mL in DCM for the formation of janus and homogeneous particles, respectively. 3 wt % PVA in ultrapure water was used as the continuous phase in generating CBZ–EC. For the synthesis of ROY–PLGA microparticles, concentrations of ROY and PLGA were set at 120 mg/mL and 10, 100 mg/mL in DCM to form janus and homogeneous particles, respectively. W and O phases were infused from opposing ends of the square capillary with syringe pumps (Harvard PHD 22/2000), where the two phases contact at the tapered tip of the cylindrical glass capillary in a flow-focusing configuration (Figure 1). Flow rates for each phase were adjusted to obtain monodisperse emulsions in the size range of 150–300 μm. 5.1 and 5.7 cm I.D. glass wells were used for sample collection as well as solidification platforms.

These glass wells were prefilled with a film (0.5 mm or 2 mm thickness) of the aqueous phase prior to the collection of 100 μL of the dispersed phase. Excess continuous phase was removed after sample collection. Evaporative solidification was done at ambient conditions (24 °C and 55% humidity). The particles were washed with ultrapure water and vacuum-dried immediately after 2 h and 5 h, for the thin and thick film cases, respectively. The predispensed film was measured to be at 0.4 mm and 1.8 mm at the end the evaporative solidification, for the thin and thick film cases, respectively. For the formation of janus and homogeneous ROY–PLGA particles, a 40 mm and 0.5 mm film was implemented respectively (see above for the respective loadings in each case); the homogeneous particles exhibit a polymer-in-drug microstructure. A 2.0 mm film implemented for solidification of the same ROY–PLGA droplets (loaded at 120 and 10 mg/mL in DCM) gave a homogeneous macrostructure and drug-in-polymer microstructure (Figure 7). For the formation of janus and homogeneous CBZ–EC particles, a 2.0 mm and 0.5 mm film was implemented, respectively. (ii) In vitro release studies: 6 mg of dry CBZ–EC microparticles were weighed out and placed into a 250 mL glass jar filled with 100 mL of ultrapure water. The glass jar was sealed

Figure 1. Experimental setup for the generation and collection of ROY–EC droplets into static thin films for evaporative solidification. Different initial solution compositions of ROY and EC were prepared in dichloromethane (DCM) and used as the dispersed phase. The continuous phase, a 1.5 wt % aqueous PVA solution, was introduced into a concentric glass capillary microfluidic device in a counter-flow configuration. Predispensed films of the continuous phase were prepared at varying thicknesses (0.5–2.0 mm) in collection dishes.
with paraffin and placed firmly in a shaker set at 115 rpm. The release media absorbance was measured at 285 nm using a Shimadzu UV-1800 UV–vis spectrophotometer.17 Samples were taken to monitor the release of carbamazepine over both short and long time scales. Measurements were made between 0–2 h at 20 min time intervals, from 2–4 h at 30 min intervals, from 4–10 h at hourly intervals, 10–120 h at 12 hourly intervals. 0.5 mL of solution was taken and replaced with fresh ultrapure water to maintain a constant buffer volume. A reference curve was also established using a series of standard solutions of carbamazepine dissolved in water at the following concentrations: 1.0, 5.0, 12.0, 18.0, 25.0, and 30.0 μg/mL. This reference curve was then used to calculate the amount of carbamazepine released at every interval. All dissolution sets were performed in triplicate.

2.3. Characterization. Optical microscopy images of the process and samples were captured using a QImaging MicroPublisher 5.0 RTV camera mounted on an Olympus SZX7 microscope. A Leica CLS 150 XE light source was used for illumination. A field emission scanning electron microscope (JEOL JSM-6700F) at 5 kV accelerating voltage was used to acquire further structural information on the microparticles. All samples were prepared on conventional SEM stubs with carbon tape and were coated with ~10 nm of platinum by sputter coating. To reveal the cross sections of the microparticles, regular Scotch tape was used to adhere and remove parts of the microparticles. Pore size distributions were obtained via digital image analysis (using ImageJ, NIH), in which 100 pores per region were measured from the cross sections of Janus and homogeneous ROY-EC microparticles. The DSC thermograms were obtained using a Mettler Toledo DSC 822 apparatus. Around 5 mg of sample was clipped in a sealed aluminum pan and heated at 3 °C/min in the range of 100–225 °C using an empty sealed pan as a reference. Dry nitrogen was used as purge gas and the N2 flow rate was 50 mL/min. The DSC instrument has a signal-to-noise ratio of ~12. Raman microscopic analysis was performed on the surface of ROY–EC microparticles using Renishaw inVia Raman spectrometer with a 514 nm laser (at a 20X objective with an accumulation time of 10 s). The curve resolution method used is the band-target entropy minimization (BTEM) algorithm.18–20 The samples were scanned from 200 to 1800 cm−1. Raman maps of 15 μm by 15 μm or 30 μm by 30 μm were obtained. Raman point-by-point mapping was performed on the mentioned area with a step size of 3 μm in both the x and y directions. The BTEM spectral estimates were then mapped back to the original data to obtain the spatial distributions of ROY. Raman measurements for the combined distribution of ROY across the maps are shown in Figure 2b,d, and pure component maps are shown in Figure S2 (see section 2 of the Supporting Information). The methodology of combining BTEM results with Raman maps and to obtain individual component spectral maps has been covered in earlier publications by Widjaja et al.3,12

3. RESULTS AND DISCUSSION

3.1. Phenomenology of Particle Structure. We first present the results of a series of experiments carried out on our chosen system system comprised of droplets of dichloromethane (DCM) containing 5-methyl-2-[[2-(nitrophenyl)-amino]-3-thiophenecarbonitrile (ROY) as the model drug and ethyl cellulose (EC) as the excipient, dispersed in an aqueous medium containing water and a small amount of poly(vinyl alcohol) (PVA) as surfactant. The basic experimental scheme is provided in Figure 1. DCM droplets containing dissolved ROY and EC (at different compositions) were first generated in an aqueous continuous phase in a simple capillary-based microfluidic emulsion generator. After generation, the droplets were dispersed as a static monolayer (in fixed quantities) into small dishes containing a thin aqueous film and left undisturbed as the DCM solvent evaporated and left the droplets, ultimately yielding solid ROY–EC particles. This system was demonstrated in a previous study, where compact drug–excipient composites were obtained upon evaporative solidification, lead to small drug crystals (<10 μm) dispersed within a solid EC matrix.14 In the present set of studies, our main aim was to explore and ultimately understand, via a simple design-of-experiments scheme, the effect of two parameters—droplet composition and solvent removal rate—on the structural outcome of the solidification process. These parameters were previously studied in tuning the morphological outcome of neat crystalline glycine particles,23 the presence of an added component—the excipient—in the current study adds another dimension of chemical and physical complexity, since two solidification processes need to be considered simultaneously, as discussed below.

We designed a set of experiments with monodisperse droplets within a narrow size range (150–300 μm mean size), at three levels of ROY and EC concentration, and conducted evaporative solidification of these droplets at two film thicknesses, to tune the solvent removal rates to nominally “high” and “low” levels. ROY and EC concentrations within the droplets were set at 120, 320, 420 mg/mL and 20, 40, 80 mg/mL, respectively, well below the experimentally determined solubility of each molecule in DCM (ROY ≈ 850 mg/mL; EC ≈ 145 mg/mL respectively), so that all experiments started with undersaturated droplets. A fixed volume of droplets was collected as a monolayer in aqueous films of two different thicknesses at 0.5 mm and 2.0 mm, and the corresponding
experimentally observed times for complete solidification were ∼2 h and ∼5 h respectively for these two cases, at all droplet compositions.

Figure 2 is a summary of the key results from these experiments, from the standpoint of particle structure. Interestingly, we observed two levels of structural control over the resultant solid particles—a coarse “macro” particle structure and a finer “micro” structure, with two possibilities in each case, leading to four combinations of observed particle structure. In general, a faster rate of solvent removal (i.e., in the thinner 0.5 mm film) and higher drug and polymer concentrations generally favored the formation of homogeneous spherical particles, in that the coarse structure was spatially uniform across the particle (Figure 2c). On the other hand, it was observed that slow rates of solvent removal (i.e., in the thicker 2 mm film) and low to moderate drug and polymer concentrations led to the formation of “janus” spherical particles, characterized by particles displaying two distinct halves of different colors (Figure 2a). Further, spatial chemical analysis via Raman microscopy measurements (Figure 2b,d) also revealed that the janus particles exhibited difference in drug content across the two halves of the particle. Finally, the macrostructural outcome was specific, in that nearly all particles in a given experimental ensemble displayed the same macrostructure. In addition, we also observed two classes of finer scale microstructure within the particles, regardless of the macrostructure obtained. In the first class of fine structure, ROY crystals were embedded within small pockets on the particle surface or within the interior, presumably surrounded by solidified EC—a structure we term “drug-in-polymer” (Figure 2e). In contrast, we also observed cases of the opposite structure, in which distinct and smooth EC domains were
found embedded within a matrix composed of tightly packed drug microcrystals; we refer to this as the "polymer-in-drug" fine structure (Figure 2f).

In the following sections, we analyze this structural diversity in terms of an interplay between three physical processes: liquid–liquid phase separation, drug crystallization, and polymer vitrification—occurring within each droplet during solvent removal.

3.2. Phenomenology of Solidification Dynamics. After describing the diversity of final particle structures obtained in our experiments, we now summarize our observations of the dynamic processes occurring within each droplet during evaporative solidification, which were common across all experimental conditions. The typical time evolution of droplets, as they gradually lose solvent (DCM), is shown in Figure 3. The first observation, as also reported previously, was that of spontaneous and rapid liquid–liquid phase separation within each droplet, which yielded a dispersion of small liquid droplets (∼1–10 μm) dispersed within each individual droplet, which coarsened with time. Such (thermodynamic) phase separation is commonly observed in solutions of pure drug/polymer in drug/polymer and solvent beyond certain threshold concentrations.29

As discussed in Section 3.2, we observed spontaneous crystallization of the outer, ROY–EC (or both) solid zone lies at ∼2 times the outer boundary of which is assumed to lie at ∼2 times the metastable zone, ROY is supersaturated, and there is therefore a finite possibility of crystal nucleation and growth.33 Likewise, ROY and EC undergo a liquid-to-gel transition in this zone, and ultimately arrests the inner droplet positions, thus leading to homogeneous structures. The pores across these particles were spatially homogeneous, with mean pore diameter of ∼3.9 μm (Figure 4b,d). Interestingly, the pore size distributions (PSDs) follow Poissonian statistics for both cases of macrostructure. This suggests that a coalescence driven mechanism in which successive coalescence events are nominally independent of each other, leading to evolution of the PSDs from exponential decays (Region 1 in Figure 4c) to skewed distributions with extended tails (Region 2 in Figure 4c,d). In all cases, we also observed that the onset of crystallization occurred when most of the DCM had been removed and the contents within the droplet reached a viscous melt-like state, which counteracted the effect of crystal density and prevented further segregation and settling.12

3.4. A Phase Diagram Perspective on the Evolution of Particle Microstructure. As discussed in Section 3.2, we observe spontaneous phase separation within the droplets, which leads to a (i) DCM-rich liquid phase, which ultimately develops into empty microscale pores, and a (ii) phase rich in ROY and EC, which solidifies into the different microstructures of Figure 2. This latter phase, rich in ROY and EC, is initially very close to the starting composition within the droplets, as demonstrated in Section 3 and Figure S3 of the Supporting Information. Next, we develop a ternary ROY–EC–DCM phase diagram for the ROY and EC-rich phase, based on mass fractions of the three major components, with the help of which we can further elucidate the various phase transitions and solidification processes occurring while the droplets lose solvent. We neglect the presence of water in this phase, since the experimentally measured solubilities of ROY and EC in DCM are used to demarcate a liquid zone in the phase diagram (Figure S5), outside which both drug and excipient are supersaturated. We also demarcate a metastable zone, the outer boundary of which is assumed to lie at ∼2 times the respective solubilities of the two solutes; outside this metastable zone lies the solid zone, in which either ROY or EC (or both) are assumed to spontaneously crystallize/vitrify. Within the metastable zone, ROY is supersaturated, and there is therefore a finite possibility of crystal nucleation and growth.35 Likewise, EC undergoes a liquid-to-gel transition in this zone, and ultimately transitions into a glassy vitrified state outside it.31
Points within Zone I represent states of the system where ROY has crossed its solubility threshold while EC has not; likewise, all points lying within Zone III represent the corresponding states of the system where EC has crossed its solubility threshold while ROY has not. Zone II indicates a territory on the phase diagram corresponding to states in which both ROY and EC have crossed their respective solubility thresholds. We also note that the ROY concentrations used in all experiments are above its solubility in ethyl cellulose, which leads to the formation of separate crystalline drug and amorphous polymer domains, instead of homogeneous amorphous solid dispersions.30

Three representative starting compositions of the ROY and EC-rich phase within the liquid zone are depicted in Figure 5. Dotted lines indicating trajectories followed by the ROY and EC-rich phase across the phase diagram are shown, along which different sequences of solidification processes are possible, depending on the initial position on the phase diagram. The trajectories are drawn on the basis of two simple assumptions: (i) that only DCM is lost as the evaporation proceeds to completion, while the ROY and EC masses (and therefore the ROY-to-EC mass ratio $r$) are conserved, and (ii) the solvent removal occurs in a quasi-static manner, so that every point along the trajectory is assumed to be at equilibrium. The trajectories are therefore also lines of constant $r$, similar to the zone boundaries drawn on the diagram. At mass ratios $r > 9$, the trajectories pass through Zone I, where ROY has crossed its solubility threshold, and therefore crystallizes prior to the vitrification of EC, thus implying that the microscale structure is predominantly the polymer-in-drug type described in Section 3.1. Conversely, at low mass ratios $r < 3.5$, the trajectory passes through Zone III, and implies that EC vitrification precedes that of ROY, thus implying that the microscale structure is predominantly the drug-in-polymer type also described in Section 3.1. For intermediate ROY to EC ratios ($3.5 < r < 9$), the system crosses over to Zone II, where drug crystallization and polymer vitrification can occur simultaneously, leading to the presence of both possible microstructures within each particle.
3.5. Insights from Dissipative Particle Dynamics (DPD) simulations. To gain further insight into the various molecular interactions in our three-component system, we conducted a series of molecular and dissipative particle dynamics (DPD) simulations as described below (full details on simulation set up may be found in Section 4 of the Supporting Information). The solubility parameters of ROY and EC were first calculated using molecular dynamics simulations, based on a methodology developed by Gupta et al. \(^{34}\) to be 21.3 and 14.8 MPa\(^{1/2}\) respectively, indicating borderline miscibility. \(^{35}\) We then conducted coarse-grained dissipative particle dynamics (DPD) simulations, where the DPD interaction parameters were obtained from the calculated solubility parameters. \(^{36}\) DPD simulation methods have previously been used in modeling phase separation of binary polymer mixtures, \(^{37}\) microphase separation in diblock copolymer systems, \(^{38}\) and micelle formation of copolymer systems in aqueous solution. \(^{39}\) We examined ROY-to-EC mass ratios ranging between 0.58–23, and DCM-to-solute (ROY + EC) mass ratios between 0.1–0.6, to mimic the traversal of the three component phase diagram from different starting compositions. Our simulations revealed a clear trend toward spatial segregation of EC and ROY molecules from each other with decreased DCM content at all ROY-to-EC mass ratios studied, as shown in Figure 6. The observed segregation is due to the borderline miscibility of EC and ROY, and similar phase behavior has been reported for indomethacin in sucrose. \(^{34,35}\) This spatial segregation at the scale of our simulations, which was carried out in cubes of \(\sim 30\) nm, lends support to the hypothesis of microstructure development described in Section 3.4 above. The segregated liquid phases eventually coarsen and solidify upon sufficient supersaturation into the corresponding solids in either the polymer-in-drug or drug-in-polymer structure.

3.6. Method Validation and in Vitro Drug Release Studies for Janus and Homogeneous Microparticles. Finally, as a proof of concept, we demonstrate structural control for two different drug–excipient systems: ROY–poly(lactic-co-glycolic acid) (PLGA) and carbamazepine-ethyl cellulose (CBZ–EC). For ROY–PLGA microparticles, we successfully fabricated both janus and homogeneous microstructures, and for the homogeneous case, we were further able to tune the internal microstructure to both polymer-in-drug and drug-in-polymer morphologies upon varying the process parameters in line with the discussions presented above (Figure 7a–d). Similarly, by varying CBZ and EC loadings and film thicknesses, we designed janus and homogeneous structured CBZ–EC microparticles (Figure 7e,f). The detailed experimental conditions are provided in Section 2.

Finally, we conducted drug release studies over 5 days on the two types of CBZ–EC microparticles, to evaluate the extent to which the structure affects drug release in this case. A drug-to-excipient mass ratio of 1 was used in fabricating both particle microstructures, and the same polymorphic form was obtained, as verified by differential scanning calorimetry (DSC) measurements (see Supporting Information, Figure S1). Figure 8a,b shows the obtained long-term and short-term release profiles respectively; both janus and homogeneous microparticles generally exhibit profiles of similar shapes, but the janus particles have a slower dissolution rate than their homogeneous counterparts. Fitting the classical Weibull model to the measurements revealed that the release does not follow simple first order kinetics \((b = 1); the b\) exponent in the model was approximately 0.5 for both cases, suggesting that the release is diffusion limited. \(^{40}\) Crucially, the janus particles released drug with a characteristic time nearly double that of the homogeneous particles, highlighting the importance and relevance of particle structure to the in vitro release profile.

This doubling of characteristic release time may be attributed to the distinct differences in porosity between the janus and homogeneous particles, as discussed in Section 3.3 above. Briefly, the homogeneous particles exhibited a uniform porosity distribution, while the janus particles exhibited a spatially segregated porosity profile with two distinct scales of porosity in the two halves. Now, the extent to which porosity at different scales affects the drug release depends on how interconnected the various sized pores are within the particle. If the smaller, submicron pores are well distributed (“mixed”) amidst the micrometer-scale pores, as in the homogeneous particles, then their respective resistances to diffusion of the drug act in parallel, and the drug release is mainly controlled by diffusion through the larger pores, which offer the least resistance. Figure 9 presents a set of SEM images of the CBZ–EC particles pre- and postrelease. Figure 9a,c are prerelease SEM images for the homogeneous and janus particles, respectively; crystalline drug is homogeneously distributed throughout the former, while it is localized in the compact, nonporous half of the latter. Next, Figure 9b,d–e illustrates the residual porosity after the dissolution and release of the trapped drug crystals. The submicron scale residual porosity in the compact half of the janus particles is apparent in Figure 9d and poses a higher diffusional resistance to drug release, hence the longer
characteristic release time than the homogeneous particles with more even initial distribution of the drug. Finally, while we did not study drug release studies for particles with polymer-in-drug microstructures, we expect different release kinetics, since it is the drug that composes the “matrix” of the particle; in such a scenario, the drug would be released at a sustainably high rate, as opposed to the inverse drug-in-polymer case, where the drug release at later times is limited by diffusion through the pores of the polymer matrix. Further detailed experimental and theoretical studies on drug release kinetics from these different particle structures are out of the scope of the present work and are the topic of ongoing investigations.

4. CONCLUSION

In summary, we have presented a detailed phenomenological study of multiscale structural design of drug−excipient microparticles using microfluidic droplet generation and subsequent evaporative solidification in thin films. Using the ROY−EC system as a prototype, by modulating the solvent removal rates and droplet compositions we control the interplay between the key physical processes in play during particle formation, leading to controlled, predictable and different morphological outcomes in the final solid particles. On the basis of this understanding, we extended the technique to fabricate ROY−PLGA and CBZ−EC microparticles with different tunable macro- and microstructures. Finally, we conducted in vitro drug release measurements from CBZ−EC microparticles with different macrostructures and found that the structural differences led to measurable differences in CBZ release kinetics. Overall, this work sheds light on the complex dynamics of particle formation from droplets containing multicomponent mixtures and suggests a method for manipulating process parameters for structural control at the single particle level. The concepts from this work are generalizable to a diversity of drug-excipient composites, for the rational engineering of novel particulate constructs with varied spatial distributions of drug(s), and hence tailored drug release profiles. Combining ideas from the thermodynamic phase behavior of multicomponent systems, and predictions of drug−polymer interactions from dissipative particle dynamics simulations and classical theories (such as Flory−Huggins theory), it is now possible to envision general algorithms for the rational design and manufacturing of such multiscale drug composites. Furthermore, the mechanisms of drug release from such composites are interesting in their own right and are the topic of ongoing work beyond this study.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.cgd.6b01701.

Crystal Growth & Design

■ AUTHOR INFORMATION

Corresponding Author
*E-mail: saifkhan@nus.edu.sg.

ORCID

Ammu Prhashanna: 0000-0002-9119-7552
Ambika Somasundar: 0000-0001-8545-0323
Qisong Xu: 0000-0002-1337-543X
Saif A. Khan: 0000-0002-7879-6147

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors gratefully acknowledge Astrid H. H. Lew for her assistance in the molecular dynamics simulations, and research funding from the GSK-EDB fund for Sustainable Manufacturing in Singapore. E.Y., D.N.Z.L., and S.A.K. thank Dr. David Lai, Dr. Sonja Sharpe, and Dr. Darryl Ertl for many stimulating discussions on microfluidics, crystallization science, and drug product development.

■ ABBREVIATIONS

API, active pharmaceutical ingredient; ROY, S-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile; EC, ethyl cellulose; CBZ, carbamazepine; PLGA, poly(lactic-co-glycolic acid); DCM, dichloromethane; PVA, poly(vinyl alcohol); PSD, pore size distribution; DPD, dissipative particle dynamics; I.D., inner diameter; r, mass ratios of ROY to EC concentrations; t, time elapsed after dispensing emulsions, time elapsed from start of in vitro drug release; m(t), normalized fraction of CBZ released from ROY-EC particles as a function of time; T_{50}, characteristic time interval for 63.2% of drug to be released; b, exponent in Weibull model; BTEM, band-target entropy minimization

■ REFERENCES

(9) Brough, C.; Williams, R. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. *Int. J. Pharm.* 2013, 453, 157−166.
(22) Widjaja, E.; Lim, G. H.; Lim, Q.; Mashadi, A. B.; Garland, M. Pure component Raman spectral reconstruction from glazed and unglazed Yuan, Ming, and Qing shards: a combined Raman microscopy and BTEM study. *J. Raman Spectrosc.* 2011, 42, 377−382.

DOI: 10.1002/cgd.6600701

Crystal Growth & Design 2017, 17, 3030−3039


